Scholar Rock (SRRK) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Twist Bioscience (TWST) has outperformed Scholar Rock (SRRK) over the past year, gaining 261.8% versus a gain of 19.7%. Over five years, SRRK leads with a +78.5% price change compared with +8.8% for TWST. Twist Bioscience is the larger company by market cap ($7.04 billion vs $5.87 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRRK | TWST |
|---|---|---|
| Share price | $48.13 | $103.32 |
| Market cap | $5.87B | $7.04B |
| 1-day change | -4.45% | -7.44% |
| YTD return | +9.26% | +225.73% |
| 1-year return | +19.70% | +261.76% |
| 5-year return | +78.46% | +8.77% |
| EPS (TTM) | $-3.23 | $-2.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $459.43M |
| Revenue growth (YoY) | — | +22.00% |
| Net income (latest FY) | $-377.94M | $-130.20M |
| Gross margin | — | 52.41% |
| Operating margin | — | -30.35% |
| Net margin | — | -28.34% |
| 52-week high | $61.76 | $219.71 |
| 52-week low | $38.69 | $28.27 |
| Distance from 52-week high | -22.07% | -52.97% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +45.56% | +24.68% |
| Average volume | 1.86M | 2.49M |
| Shares outstanding | 122.00M | 68.18M |
| Employees | 289 | 1,080 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed SRRK by 242.1 percentage points over the past year.
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees
SRRK vs TWST FAQ
Which is bigger, Scholar Rock or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $5.87B for Scholar Rock (SRRK).
Which stock has performed better over the past year, SRRK or TWST?
TWST returned +261.76% over the past 12 months, compared with +19.70% for SRRK (price return, excluding dividends). Past performance does not predict future results.
Are Scholar Rock and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.